论文部分内容阅读
目的探讨帕罗西汀治疗脑卒中后抑郁症患者的临床疗效和安全性。方法选取2014年9月至2016年9月四平市中心医院收治的107例脑卒中后抑郁症患者作为研究对象,根据随机数字表法将其分为常规组(53例)与研究组(54例)。常规组患者给予常规对症支持治疗,研究组患者在对照组基础上采用帕罗西汀进行治疗,比较两组患者临床疗效、汉密尔顿抑郁量表(HAMD)评分、美国国立卫生研究院卒中量表(NIHSS)评分、生命质量评分及不良反应发生情况。结果研究组患者治疗的总有效率明显高于常规组,差异有统计学意义(P<0.05);治疗后,研究组患者HAMD评分、NIHSS评分均明显低于常规组,差异均有统计学意义(均P<0.05);研究组患者躯体功能、物质生活、心理功能、社会功能评分均明显高于常规组,差异均有统计学意义(均P<0.05);两组患者不良反应发生率差异无统计学意义(P>0.05)。结论脑卒中后抑郁症患者应用帕罗西汀治疗临床效果显著,可明显减轻患者抑郁程度及神经缺损程度,提高患者生命质量,且安全性较高。
Objective To investigate the clinical efficacy and safety of paroxetine in the treatment of post-stroke depression. Methods A total of 107 patients with post-stroke depression who were admitted to Siping Central Hospital from September 2014 to September 2016 were selected and divided into two groups: conventional group (53 cases) and study group (54 cases) ). Patients in the study group were treated with paroxetine on the basis of the control group. The clinical efficacy, Hamilton Depression Rating Scale (HAMD), NIHSS (National Institutes of Health Stroke Scale) Score, quality of life score and adverse reactions. Results The total effective rate of treatment in study group was significantly higher than that in routine group (P <0.05). After treatment, the scores of HAMD and NIHSS in study group were significantly lower than those in routine group (All P <0.05). The body function, material life, psychological function and social function score of the study group were significantly higher than those of the conventional group (all P <0.05). There was no significant difference in the incidence of adverse reactions between the two groups No statistical significance (P> 0.05). Conclusion The clinical effect of paroxetine in patients with post-stroke depression is significant, which can significantly reduce the extent of depression and neurological deficits, improve the quality of life of patients and have higher safety.